VRTX · Vertex Pharmaceuticals Inc.

S&P 500 #98 · NASDAQ-100 #38 · Nasdaq

Risiko 5/10 · Defensive Biotech with Pipeline Optionality · $490.39 ▲ 2.38%

Kennzahlen

• Price $490.39
• Market cap $124.5B
• P/E (ttm) 29.09
• Div yield none
• 52-wk range $362.50 – $533.67
• Index rank #98 / #38

Wichtigste Risiken

• Cystic fibrosis franchise revenue concentration (Revenue sustainability) — HIGH
• Pipeline clinical trial failure risk (Growth thesis) — MED
• Drug pricing legislation (IRA impact) (Margins) — MED
• No dividend — capital allocation depends on M&A (Investors) — LOW

Fazit

Vertex Pharmaceuticals dominates the cystic fibrosis market with Trikafta and is expanding into pain, kidney disease, and cell therapies, providing a durable growth runway.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.